Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation. For metabolic and cardiovascular health, their offerings comprise Xuezhikang, a lipid-regulating drug for hypercholesterolaemia; Beixi, an acarbose capsule for Type 2 diabetes; and Beitangning, a pioglitazone hydrochloride capsule designed to manage blood glucose. In neurology and psychiatry, Luye Pharma provides Maitongna for cerebral edema resulting from trauma or surgery, and for venous reflux disorders. Their pipeline features the Rivastigmine Transdermal Patch for Alzheimer's disease; Fentanyl Transdermal Patch for cancer-related pain; and Buprenorphine Transdermal Patch for chronic pain. They also market Seroquel and Seroquel XR for schizophrenia and manic episodes of bipolar affective disorders, alongside Rykindo, an injectable treatment for schizophrenia. Other specialized products include Nuosen for acute upper digestive tract hemorrhage; Sailimai for the management of diarrhea; the Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for localized swelling; Oukai, for soft tissue swelling and venous edema; and Fengshiye, intended for patients experiencing bone, joint, and limb pain. Beyond traditional pharmaceuticals, the company also extends its operations to include the manufacturing and commercialization of biopharmaceutical products. Luye Pharma Group Ltd. was established in 1994 and is headquartered in Yantai, People's Republic of China.
The current price of LYPHF is $0.28 USD — it has increased by +0% in the past 24 hours. Watch Luye Pharma Group stock price performance more closely on the chart.
What is Luye Pharma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Luye Pharma Group stocks are traded under the ticker LYPHF.
Is Luye Pharma Group stock price growing?▼
LYPHF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Luye Pharma Group has showed a +0.75% increase.
What is Luye Pharma Group market cap?▼
Today Luye Pharma Group has the market capitalization of 1.08B
When is the next Luye Pharma Group earnings date?▼
Luye Pharma Group is going to release the next earnings report on March 31, 2027.
What were Luye Pharma Group earnings last quarter?▼
LYPHF earnings for the last quarter are 0 USD per share, whereas the estimation was 0.01 USD resulting in a -48.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Luye Pharma Group revenue for the last year?▼
Luye Pharma Group revenue for the last year amounts to 891.07M USD.
What is Luye Pharma Group net income for the last year?▼
LYPHF net income for the last year is 87.4M USD.
Does Luye Pharma Group pay dividends?▼
Yes, LYPHF dividends are paid semi-annual. The last dividend per share was 0.01 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Luye Pharma Group have?▼
As of September 04, 2026, the company has 5,221 employees.
In which sector is Luye Pharma Group located?▼
Luye Pharma Group operates in the Health & Wellness sector.
When did Luye Pharma Group complete a stock split?▼
Luye Pharma Group has not had any recent stock splits.
Where is Luye Pharma Group headquartered?▼
Luye Pharma Group is headquartered in Yantai, Bermuda.